

Gordon Rees Scully Mansukhani, LLP
655 University Avenue, Suite 200
Sacramento, CA 95825

1 KATHLEEN M. RHOADS (SBN: 144466)
2 GORDON REES SCULLY MANSUKHANI, LLP
3 655 University Avenue, Suite 200
4 Sacramento, CA 95825
5 Telephone: (916) 565-2900
6 Facsimile: (916) 920-4402
7 Email: krhoads@grsm.com

8 Attorneys for Defendant
9 TEVA PHARMACEUTICALS USA, INC.

10 UNITED STATES DISTRICT COURT
11 EASTERN DISTRICT OF CALIFORNIA

12 TOBY HENRY,) CASE NO. 2:17-cv-02593-TLN-KJN
13)
14 Plaintiff,)
15)
16 vs.) **STIPULATION AND PROPOSED**
17) **ORDER EXTENDING DEADLINE FOR**
18) **DEFENDANT TEVA**
19) **PHARMACEUTICALS USA, INC. TO**
20) **RESPOND TO PLAINTIFF'S**
21) **COMPLAINT**
22)
23 ANGELINI PHARMA INC., ANGELINI,)
24) ANGELINI LABOPHARM LLC, ENDO,)
25) ENDO HEALTH SOLUTIONS, INC., ENDO)
26) INTERNATIONAL PLC, ENDO)
27) PHARMACEUTICALS, INC., GRUPPO)
28) ANGELINI, LABOPHARM INC.,)
29) LABOPHARM USA, INC., PALADIN LABS)
30) INC., TEVA PHARMACEUTICALS USA,)
31) INC., and DOES 1 through 100,)
32)
33 Defendants.)
34)

35 **STIPULATION TO EXTEND TIME TO RESPOND**

36 IT IS HEREBY STIPULATED, by and between Plaintiff Toby Henry (“Plaintiff”) and
37 Defendant Teva Pharmaceuticals USA, Inc. (“Teva”) as follows:

38 WHEREAS Plaintiff filed his Complaint for Damages in the above-captioned action on
39 December 12, 2017;

40 WHEREAS Plaintiff’s Complaint and corresponding Summons were served on Teva on
41 December 26, 2017;

42 WHEREAS, on January 31, 2018, the Hon. Troy L. Nunley signed an Order extending

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

the deadline for Teva’s response to the Complaint to February 13, 2018 based upon a Stipulation between counsel for Plaintiff and Teva and good cause appearing thereon [Doc. 15];

WHEREAS counsel for Plaintiff and counsel for Teva are currently engaged in ongoing discussions regarding how this action should proceed and collectively agree Teva should have until March 12, 2018 to file a response to the Complaint;

WHEREAS Plaintiff and Teva are the only parties impacted by this Stipulation and this Stipulation will not result in prejudice to any party;

NOW THEREFORE, Plaintiff and Teva, by and through their counsel of record, hereby stipulate and agree that Teva should have until March 12, 2018 to file a response to the Complaint under FRCP Rule 12.

Nothing in the Stipulation shall constitute a waiver of any arguments or defenses that Teva or Plaintiff may wish to assert in the future, all of which are expressly reserved.

IT IS SO STIPULATED AND AGREED.

Respectfully submitted,

Dated: February 12, 2018

LAW OFFICES OF LAWRENCE PAIKOFF

/s/ Richard J. Paikoff

By: _____
LAWRENCE S. PAIKOFF
Richard J. Paikoff
Attorney for Plaintiff
TOBY HENRY

Dated: February 12, 2018

GORDON REES SCULLY MANSUKHANI, LLP

/s/ Kathleen M. Rhoads

By: _____
KATHLEEN M. RHOADS
Attorneys for Defendant
TEVA PHARMACEUTICALS USA, INC.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ORDER

Based upon the foregoing Stipulation and good cause appearing. IT IS HEREBY ORDERED that Defendant Teva may file its response to the Complaint under FRCP Rule 12 by March 12, 2018.

IT IS SO ORDERED.

Dated: 2/12/2018



Troy L. Nunley
United States District Judge